IGIP19008 / ERYTECH Pharma / Aram HezelResearch Question:
Does the the addition of eryaspase to chemotherapy improve patient health compared
to chemotherapy alone?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This is an open-label, multicenter, randomized, Phase 3 study in patients with ductal
adenocarcinoma of the pancreas who have failed only one prior line of systemic anti-cancer
therapy for advanced pancreatic cancer and have measurable disease.
Study Reference #: IGIP19008
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search